WVE Earnings Prediction
The chart below shows how WVE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, WVE sees a +4.04% change in stock price 10 days leading up to the earnings, and a +2.37% change 10 days following the report. On the earnings day itself, the stock moves by +3.40%. This data can give you a slight idea of what to expect for the next quarter's release.
WVE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
-7.68M
-115.60%
-138.98%
Gross Margin
--
--
--
Operating Margin
-543.17%
-6115.17%
205.63%
Net Margin
-514.22%
-3588.60%
207.57%
EPS
-0.47
-771.43%
88.00%
No Data Available
WVE Earnings Analysis
Wave Life Sciences Ltd. Ordinary Shares Corporation (WVE.O) Earnings Conference Call
Positive
Clinical Data Success: Wave Life Sciences executed ahead of plan, delivering three positive clinical data sets this year.
FDA Support for Obesity Program: Received supportive initial feedback from FDA on HD, rapidly advancing our obesiity program towards the clinic.
RNA Platform Advancements: Our best-in-class RNA platform is consistently translating in the clinic, demonstrating unique design and advancement of RNA medicine.
Accelerated Approval Progress: We are advancing WVE-N531 in DMD and WVE-003 in HD towards potential accelerated approval.
Huntington Reduction and Atrophy: We observed a statistically significant correlation between mutant Huntington reduction and slowing of caudate atrophy.
Negative
Revenue Decline Analysis: Revenue decreased by 15% year-over-year, totaling $50 million compared to $59 million in the same quarter last year.
Widening Net Loss: Net loss widened to $10 million, up from a loss of $5 million in the previous year, indicating a deteriorating financial position.
Operating Expenses Surge: Operating expenses increased by 20%, reaching $30 million, which significantly impacted profitability.
Customer Growth Decline: Customer growth stagnated, with only 1,000 new customers added this quarter, compared to 5,000 in the previous quarter.
R&D Spending Reduction: R&D spending was cut by 25%, totaling $5 million, raising concerns about future product development and innovation.
WVE FAQs
How does WVE typically perform around its earnings report dates?
Is Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
WVE Earning Call Sentiment
Wave Life Sciences Ltd. (WVE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
WVE.O
-1.77%Positive
The earnings call reveals financial struggles with a significant net loss, increased R&D expenses, and no shareholder return plan. Despite positive trial results and potential partnerships, competitive pressures and financial risks weigh heavily. The Q&A section highlights uncertainties in regulatory pathways and management's evasive responses, further undermining confidence. The lack of new partnerships or shareholder returns, coupled with financial challenges, suggests a likely negative stock price reaction.
